Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: A systematic review and network meta-analysis

International Journal of COPD

Volumn 10, Issue 1, 2015, Pages 2495-2517

  Ismaila, Afisi Segun ^a,b   Huisman, Eline L ^c   Punekar, Yogesh Suresh ^d   Karabis, Andreas ^c  

^a GLAXOSMITHKLINE   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c MAPI GROUP   (Netherlands)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Anticholinergics; Bronchodilator; Meta analysis; Muscarinic antagonist; Systematic review

Indexed keywords

ACLIDINIUM BROMIDE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; GLYCOPYRRONIUM BROMIDE; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; SALBUTAMOL; STEROID; THEOPHYLLINE; TIOTROPIUM BROMIDE; UMECLIDINIUM; BRONCHODILATING AGENT; GLYCOPYRRONIUM; QUINUCLIDINE DERIVATIVE; TROPANE DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MONOTHERAPY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SMOKING; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT DURATION; BAYES THEOREM; CONVALESCENCE; DRUG ADMINISTRATION; DRUG EFFECTS; LUNG; MIDDLE AGED; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPIROMETRY; TIME FACTOR; TREATMENT OUTCOME;

AGED; BAYES THEOREM; BRONCHODILATOR AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FORCED EXPIRATORY VOLUME; GLYCOPYRROLATE; HUMANS; LUNG; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINUCLIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOVERY OF FUNCTION; SPIROMETRY; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TIOTROPIUM BROMIDE; TREATMENT OUTCOME; TROPANES;

EID: 84947432890     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S92412     Document Type: Article

References (29)

1. Chan CKN, Maltais F, Sigouin C, Haddon JM, Ford GT. A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease. Can Respir J. 2007;14:465-472.
2. Spiriva Assessment of FEV1 (SAFE). The effect of inhaled tiotropium bromide (18 mcg once daily) on the change in FEV1 during long-term treatment in patients with COPD. A one-year parallel group, double-blind, randomised, placebo-controlled study. Boehringer Ingelheim Clinical Trial Register. NLM: NCT00277264. 2005. Available from: http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/205/205.259_U05-3345.pdf. Accessed October 19, 2015.
3. Spiriva® Assessment of FEV1 (SAFE). Boehringer Ingelheim. 2013. NLM identifier: NCT00277264. Available from: http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/205/205.259_U05-3345.pdf. Accessed October 19, 2015.
4. Spiriva (Tiotropium Bromide) Assessment of FEV1 - (SAFE-Portugal). Boehringer Ingelheim. 2013. NLM identifier: NCT00239408. Available from: http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/205/205.282_U06-2124.pdf. Accessed October 19, 2015.
5. Tonnel AB, Perez T, Grosbois JM, Verkindre C, Bravo ML, Brun M. Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD. Int J Chron Obstruct Pulmon Dis. 2008;3: 301-310.
6. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543-1554.
7. Evaluation of the long-term effects of spiriva on lung function in COPD patients. Boehringer Ingelheim. 2005. NLM identifier: NCT00144339.
8. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med. 2005;143:317-326.
9. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2003;58:399-404.
10. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest. 2002;122:47-55.
11. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19:217-224.
12. Donohue JF, Fogarty C, Lotvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182:155-162.
13. Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42:1484-1494.
14. D'Urzo A, Ferguson GT, van Noord JA, et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res. 2011;12:156.
15. Kerwin E, Hebert J, Gallagher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J. 2012;40:1106-1114.
16. Verkindre C, Bart F, Aguilaniu B, et al. The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration. 2006;73:420-427.
17. Casaburi R, Briggs DD, Donohue JF, Serby CW, Menjoge SS, Witek TJ. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD - a 13-week multicenter trial. Chest. 2000;118:1294-1302.
18. Covelli H, Bhattacharya S, Cassino C, Conoscenti C, Kesten S. Absence of electrocardiographic findings and improved function with once-daily tiotropium in patients with chronic obstructive pulmonary disease. Pharmacotherapy. 2005;25:1708-1718.
19. Garcia RF. A randomised, double-blind, placebo-controlled, 12 weeks trial to evaluate the effect of Tiotropium Inhalation Capsules on the magnitude of exercise, measured using an accelerometer, in patients with Chronic Obstructive Pulmonary Disease (COPD). Boehringer Ingelheim Trial Results. 2007. NLM Identifier: NCT00144326. Available from: http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/205/205.269.pdf. Accessed October 19, 2015.
20. Moita J, Barbara C, Cardoso J, et al. Tiotropium improves FEV1 in patients with COPD irrespective of smoking status. Pulm Pharmacol Ther. 2008;21:146-151.
21. Vogelmeier C, Kardos P, Harari S, Gans SJM, Stenglein S, Thirlwell J. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med. 2008;102:1511-1520.
22. Kerwin EM, D'Urzo AD, Gelb AF, Lakkis H, Garcia GE, Caracta CF. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD. 2012;9:90-101.
23. Rennard SI, Scanlon PD, Ferguson GT, et al. ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clin Drug Invest. 2013;33:893-904.
24. Jones PW, Singh D, Bateman ED, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J. 2012;40:830-836.
25. GlaxoSmithKline. Clinical Study Report - DB2113373. 2013.
26. Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013;107:1538-1546.
27. GlaxoSmithKline. Clinical Study Report - AC4115408. 2013.
28. Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1:199-209.
29. Chapman KR, Beeh KM, Beier J, et al. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulm Med. 2014;14:4.